The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of RNK08954 in patients with advanced solid tumors with a KRAS G12D mutation.
 
Iman El-Hariry
Employment - Ranok Therapeutics
Leadership - 7 Hills Pharma
 
Weiwen Ying
Employment - Ranok Therapeutics
Leadership - Ranok Therapeutics
Stock and Other Ownership Interests - Ranok Therapeutics
 
Yan Dai
Employment - Ranok Therapeutics
 
Kevin Foley
Employment - Ranok Therapeutics
Leadership - Ranok Therapeutics
Patents, Royalties, Other Intellectual Property - Ranok Therapeutics
 
Zhengbo Song
No Relationships to Disclose
 
Xin Wu
Employment - Ranok Therapeutics
 
Rong Liang
No Relationships to Disclose
 
Jun Zhang
No Relationships to Disclose
 
Xiangcai Yang
No Relationships to Disclose